sponsored
PatientsVille.com Logo

PatientsVille

Entecavir Medical Research Studies

Up-to-date List of Entecavir Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Entecavir Medical Research Studies

Rank Status Study
1 Recruiting Comparison Between Lamivudine and Entecavir Treatment in Patients
Condition: Chronic Hepatitis B
Interventions: Drug: Lamivudine;   Drug: Entecavir
Outcome Measures: Overall survival (OS) rate during observational period;   Change from baseline in HBV DNA level at each visit;   Proportion of subjects with HBV DNA response at each visit;   Change from baseline in ALT and AST level at each visit;   Change from baseline in bilirubin level at each visit;   Proportion of subjects with prolonged PT at each visit;   Transplantation-free survival rate during observational period;   To assess the safety of lamivudine and Entecavir treatments in patients with HBV-associated severe acute exacerbation.
2 Recruiting Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B
Condition: Chronic Hepatitis B
Intervention: Drug: Pegasys&Entecavir
Outcome Measures: Simultaneous achievement of HBsAg below 100 IU/mL and HBV DNA<300 IU/mL;   serum HBV DNA <2000 IU/mL,HBsAg <1000 IU/mL,ALT normalization,HBsAg loss,Entecavir resistance, HBsAg seroconversion,Fibrosis stages
3 Recruiting Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir and peginterferon alfa-2a;   Drug: Placebo and peginterferon
Outcome Measure: HBeAg seroconversion rate 6 months after the cessation of therapy
4 Recruiting Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir and peginterferon (Pegasys) (52 weeks);   Drug: Peginterferon (Pegasys) (96 weeks);   Drug: Peginterferon (Pegasys) (48 weeks)
Outcome Measures: HBV virologic response (HBV DNA < 2,000 IU/mL) 6 months after the cessation of treatment;   ALT normalization rate (ALT < 40 IU/L) 6 months after the cessation of treatment
5 Unknown  Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients
Conditions: Chronic Hepatitis B;   Hepatic Steatosis
Interventions: Drug: Entecavir;   Drug: essentiale + Entecavir;   Drug: Vitamin E + Entecavir
Outcome Measures: Differences in the anti-viral effect of Entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs;   Differences in the sustained response rate to Entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs and obtained anti-virus effect after 1 year treatment.;   Differences in the anti-viral effect of Entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs in a short term.
6 Unknown  Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)
Condition: Chronic Hepatitis B
Intervention: Drug: Pegalyted interferon, Entecavir
Outcome Measure: Combination of half dose and reduced duration pegalyted interferon in combination with Entecavir achieves biochemical and virologic response in chronic hepatitis B
7 Unknown  Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B
Condition: Chronic Hepatitis B
Interventions: Drug: Pegasys plus Entecavir;   Drug: Entecavir
Outcome Measures: HBeAg seroconversion;   Serum ALT normalization, HBeAg loss, serum HBV DNA disappearance, HBsAg disappearance, histologic change, Entecavir resistance
8 Not yet recruiting Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment
Conditions: Hepatitis;   Tuberculosis;   hepatitisB
Intervention: Drug: Entecavir (BARACLUDE®)
Outcome Measures: incidence of hepatitis;   HBV viral load
9 Unknown  Lactic Acidosis During Entecavir(ETV)Treatment
Condition: Lactic Acidosis
Intervention: Drug: Entecavir, lamivudine
Outcome Measures: incidence of elevated venous lactate levels more than 2 mmol/L of any etiology;   incidence of elevated venous lactate levels more than 2 mmol/L directly related to NRTI;   Incidence of elevated venous lactate levels more than 2 mmol/L caused by etiologies other than NTRIs;   Frequency of concomitant prescribed medications possibly associated with lactic acidosis other than NTRIs;   Arterial pH and anion gap in cases with elevated blood lactate levels (at the time of detection and peak levels;   Overall OLT-free survival
10 Recruiting Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B
Condition: Chronic Viral Hepatitis B Without Delta-agent
Interventions: Drug: Telbivudine;   Drug: Entecavir
Outcome Measures: HBsAg titer at 48 weeks;   Proportion of patients with serum HBsAg decline of ≥0.5 log10 IU/mL and <1.0 log10 IU/mL;   Proportion of patients with serum HBsAg decline greater than 1.0 log10 IU/mL;   Proportion of patients with serum HBsAg loss;   Proportion of patients with serum HBeAg loss or HBeAg seroconversion;   Proportion of patients with virologic rebound or genotypic resistance;   Proportion of patients with normal ALT;   Adverse events: Creatine kinase level, GFR, Muscle events, Other AEs
11 Recruiting Switching to Tenofovir Versus Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study
Condition: Chronic Hepatitis B
Interventions: Drug: tenofovir;   Drug: Entecavir
Outcome Measures: Virologic response rate at year 1 (12 months) (HBV DNA < 20 IU/mL);   -Degree of HBV DNA reduction, mean HBV DNA, biochemical and serologic response rates, resistance, and adverse events at year 1
12 Recruiting Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir
Conditions: Liver Transplantation;   Hepatitis B;   Liver Disease
Intervention: Drug: Entecavir
Outcome Measures: prevention of hepatitis B virus reinfection one year after liver transplantation with Entecavir monotherapy;   hepatitis Bs antigen negativity can be maintained by Entecavir in the second year after HBV induced liver transplantation
13 Unknown  Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss
Condition: Hepatitis B
Interventions: Drug: Entecavir;   Drug: Peginterferon alfa-2a
Outcome Measures: HBeAg sericonversion rate;   HBeAg loss rate;   HBeAg quantification dynamic change;   HBsAg loss rate;   HBsAg seroconversion rate;   HBsAg quantification dynamic change;   ALT normalization rate
14 Unknown  Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B
Condition: Chronic Hepatitis B
Intervention: Drug: PEG-IFN and Entecavir
Outcome Measures: To determine whether a combination of PEG-IFN and Entecavir improves the rate of sustained response and HBsAg clearance in patients with HBeAg-negative chronic hepatitis B;   To determine host factors and viral factors associated with response to PEG-IFN alone or PEG-IFN plus Entecavir treatment
15 Recruiting Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
Conditions: Non-Hodgkin Lymphoma;   Hepatitis B Reactivation
Interventions: Drug: Entecavir;   Drug: Lamivudine
Outcome Measures: Incidence rate of HBV reactivation;   Incidence rate of hepatitis and HBV reactivation-related hepatitis;   Incidence rate and median time of treatment delay due to hepatitis;   Incidence rate and median time of HBV DNA level normalization
16 Recruiting Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir
Condition: Chronic Hepatitis B
Interventions: Drug: Telbivudine;   Drug: Tenofovir;   Drug: Entecavir
Outcome Measures: HBV DNA non-detectability;   Reduction of HBV DNA from baseline;   HBeAg loss or HBeAg seroconversion;   HBsAg loss or HBsAg seroconversion;   ALT normalization;   Accumulate rate of Viral breakthrough;   Accumulate rate of Biochemical Breakthrough;   Accumulate rate of genotypic mutation in HBV;   Change of eGFR from baseline;   Accumulate rate of CK abnormal elevation;   Accumulate rate of symptom related muscular disease;   Accumulate rate of Adverse event or serious adverse event
17 Unknown  Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir;   Drug: Lamivudine
Outcome Measures: Percentage number of patients with HBV DNA < 60 IU/mL (Undetectable serum HBV DNA by PCR method) while on randomized therapy;   Percentage number of patients who achieved ALT normalization, HBeAg loss, HBe seroconversion, HBsAg loss and HBs seroconversion;   Cumulative discontinuation rates due to lamivudine or Entecavir resistance mutations and clinical breakthrough, Safety assessment
18 Recruiting Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
Condition: Hepatitis B
Interventions: Drug: Entecavir prophylaxis;   Drug: Therapeutic Entecavir
Outcome Measures: the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis;   the incidence of hepatitis B virus maintained response, the incidence of hepatitis B virus sustained response, the incidence of hepatitis B virus relapse and hepatitis B virus relapse related hepatitis
19 Recruiting Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B
Condition: Chronic Hepatitis B
Interventions: Drug: Peg-IFNα-2a;   Drug: Entecavir
Outcome Measures: the rates of HBeAg seroconversion;   normalisation of ALT;   liver histological improvement;   The rates of HBsAg negative;   the rate of virological response;   the rate of HBeAg negative
20 Recruiting Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
Condition: Hepatitis B
Intervention: Drug: Entecavir and peginterferon
Outcome Measures: Safety: Number, type and rate of adverse events/serious adverse events through treatment and end of follow-up 48 weeks after stopping treatment. Efficacy: HBeAg loss (lack of detectable HBeAg) AND HBV DNA ≤1,000 IU/mL 48 weeks after stopping treatment.;   HBeAg loss;   HBeAg seroconversion;   Time to HBsAg loss;   ALT <45 IU/L for men, <30 IU/L for women (approximately 1.5 ULN);   ALT normalization (men <30 IU/L, women <20 IU/L);   HBV DNA ≤1000 IU/mL;   HBV DNA <20 IU/mL (LLOQ of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)

These studies may lead to new treatments and are adding insight into Entecavir etiology and treatment.

A major focus of Entecavir research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Entecavir